Akebia Therapeutics, Inc. (AKBA)

NCM – Real Time Price. Currency in USD

1.18

+0.03 (2.61%)

At close: May 12, 2026, 4:00 PM EDT

1.17

-0.01 (-0.81%)

After-hours: May 12, 2026, 7:44 PM EDT

07.05.2026

Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript

07.05.2026

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.

07.05.2026

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025 Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST CAMBRIDGE, Mass.

04.05.2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 208,800 shares of Akebia's common stock on April 30, 2026.

04.05.2026

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the Journal of the American Society of Nephrology (JASN), a leading, high-impact, peer-reviewed journal in nephrology.

28.04.2026

New Strong Sell Stocks for April 28th

EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.

13.04.2026

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being evaluated for the treatment of cardiac surgery-associated acute kidney injury (AKI).

Videos

No Data

There is no data to display

Press releases

07.05.2026

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

04.05.2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 208,800 shares of Akebia's common stock on April 30, 2026.

04.05.2026

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the Journal of the American Society of Nephrology (JASN), a leading, high-impact, peer-reviewed journal in nephrology.

13.04.2026

Akebia Therapeutics, Inc. (AKBA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

New Strong Sell Stocks for April 28th

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Videos

No Data

Press releases

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

New Strong Sell Stocks for April 28th

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Videos

No Data

Press releases

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Search stocks

Akebia Therapeutics, Inc. (AKBA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

New Strong Sell Stocks for April 28th

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Videos

No Data

Press releases

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

New Strong Sell Stocks for April 28th

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Videos

No Data

Press releases

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090